Cumberland Pharmaceuticals (NASDAQ:CPIX) Share Price Crosses Above Two Hundred Day Moving Average – Time to Sell?

Shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $3.37 and traded as high as $3.96. Cumberland Pharmaceuticals shares last traded at $3.92, with a volume of 93,905 shares.

Wall Street Analysts Forecast Growth

CPIX has been the subject of several research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a report on Monday, December 29th. Wall Street Zen raised Cumberland Pharmaceuticals to a “hold” rating in a research note on Saturday, January 10th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Cumberland Pharmaceuticals has a consensus rating of “Sell”.

Cumberland Pharmaceuticals Price Performance

The company’s 50-day simple moving average is $4.14 and its 200 day simple moving average is $3.37. The company has a market cap of $58.64 million, a PE ratio of -16.33 and a beta of -0.52. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.11 and a current ratio of 1.23.

Hedge Funds Weigh In On Cumberland Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Perceptive Advisors LLC purchased a new stake in shares of Cumberland Pharmaceuticals during the fourth quarter worth approximately $1,358,000. Marshall Wace LLP purchased a new stake in shares of Cumberland Pharmaceuticals in the 4th quarter valued at approximately $192,000. Geode Capital Management LLC increased its position in shares of Cumberland Pharmaceuticals by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 107,274 shares of the specialty pharmaceutical company’s stock valued at $427,000 after purchasing an additional 5,653 shares during the last quarter. Two Sigma Investments LP raised its holdings in shares of Cumberland Pharmaceuticals by 16.5% in the 3rd quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock valued at $117,000 after purchasing an additional 5,326 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Cumberland Pharmaceuticals by 11.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 280,869 shares of the specialty pharmaceutical company’s stock worth $876,000 after purchasing an additional 27,980 shares during the last quarter. Hedge funds and other institutional investors own 15.51% of the company’s stock.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.